DK3843723T3 - Sammensætning til udryddelse af helicobacter pylori - Google Patents

Sammensætning til udryddelse af helicobacter pylori

Info

Publication number
DK3843723T3
DK3843723T3 DK19855537.7T DK19855537T DK3843723T3 DK 3843723 T3 DK3843723 T3 DK 3843723T3 DK 19855537 T DK19855537 T DK 19855537T DK 3843723 T3 DK3843723 T3 DK 3843723T3
Authority
DK
Denmark
Prior art keywords
composition
helicobacter pylori
eradicating helicobacter
eradicating
pylori
Prior art date
Application number
DK19855537.7T
Other languages
Danish (da)
English (en)
Inventor
Bong Tae Kim
Dongkyu Kim
Eun Ji Kim
Ji Won Lee
Kyeongmin Oh
Ahrong Kim
Geun Seog Song
Shin-Young Ryu
Eun Kyung Kim
Naree Shin
Hyun Ji Kang
Jae Min Kim
Yu-Gyeong Park
Haneul Jeong
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Application granted granted Critical
Publication of DK3843723T3 publication Critical patent/DK3843723T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK19855537.7T 2018-08-29 2019-08-28 Sammensætning til udryddelse af helicobacter pylori DK3843723T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180102250 2018-08-29
PCT/KR2019/011017 WO2020045992A1 (en) 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori

Publications (1)

Publication Number Publication Date
DK3843723T3 true DK3843723T3 (da) 2026-02-09

Family

ID=69643254

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19855537.7T DK3843723T3 (da) 2018-08-29 2019-08-28 Sammensætning til udryddelse af helicobacter pylori

Country Status (25)

Country Link
US (2) US20210196685A1 (https=)
EP (1) EP3843723B1 (https=)
JP (1) JP7189327B2 (https=)
KR (1) KR20200026118A (https=)
CN (1) CN112638378A (https=)
AR (1) AR116026A1 (https=)
AU (1) AU2019328903B2 (https=)
CA (1) CA3107624C (https=)
DK (1) DK3843723T3 (https=)
EA (1) EA202190622A1 (https=)
ES (1) ES3060114T3 (https=)
FI (1) FI3843723T3 (https=)
GE (2) GEP20227431B (https=)
JO (1) JOP20190201B1 (https=)
LT (1) LT3843723T (https=)
MX (1) MX2021002278A (https=)
MY (1) MY195494A (https=)
PH (1) PH12021550385A1 (https=)
PT (1) PT3843723T (https=)
RS (1) RS67791B1 (https=)
SG (1) SG11202101920WA (https=)
SI (1) SI3843723T1 (https=)
UA (1) UA126993C2 (https=)
UY (1) UY38348A (https=)
WO (1) WO2020045992A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3132575A1 (en) * 2019-04-18 2020-10-22 Thomas Julius Borody Compositions and methods for treating, ameliorating and preventing h. pylori infections
WO2024210689A1 (ko) * 2023-04-07 2024-10-10 제이더블유중외제약 주식회사 벤즈이미다졸 유도체의 염
TW202535382A (zh) * 2023-11-29 2025-09-16 南韓商第一藥品股份有限公司 包含ｚａｓｔａｐｒａｚａｎ或其醫藥上可接受的鹽之用於幽門螺旋桿菌根除的組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753324B2 (en) * 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
KR101088247B1 (ko) * 2005-12-19 2011-11-30 라퀄리아 파마 인코포레이티드 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도
CN101015694A (zh) * 2006-02-07 2007-08-15 沈阳东宇药业有限公司 一种治疗幽门螺旋杆菌感染的复方口服制剂
HUE056322T2 (hu) * 2015-06-08 2022-02-28 Hk Inno N Corp Benzimidazol-származék alkalmazásai éjszakai savvisszaáramláshoz
WO2017125912A1 (en) * 2016-01-21 2017-07-27 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
CN108379258B (zh) * 2017-11-30 2020-02-18 中国医学科学院医药生物技术研究所 瑞香素在抗幽门螺杆菌中的应用

Also Published As

Publication number Publication date
EP3843723A1 (en) 2021-07-07
UY38348A (es) 2020-03-31
KR20200026118A (ko) 2020-03-10
SG11202101920WA (en) 2021-04-29
MX2021002278A (es) 2021-08-11
WO2020045992A1 (en) 2020-03-05
CA3107624C (en) 2023-10-03
BR112021003578A2 (pt) 2021-05-18
AU2019328903A1 (en) 2021-04-29
CN112638378A (zh) 2021-04-09
ES3060114T3 (https=) 2026-03-25
GEP20227431B (en) 2022-10-25
LT3843723T (lt) 2026-03-25
EP3843723A4 (en) 2022-06-29
AU2019328903A8 (en) 2021-05-27
UA126993C2 (uk) 2023-03-01
PH12021550385A1 (en) 2021-09-20
CA3107624A1 (en) 2020-03-05
MY195494A (en) 2023-01-26
JOP20190201A1 (ar) 2020-02-29
US20250241897A1 (en) 2025-07-31
JP2021535910A (ja) 2021-12-23
AR116026A1 (es) 2021-03-25
US20210196685A1 (en) 2021-07-01
PT3843723T (pt) 2026-01-27
EP3843723B1 (en) 2026-01-07
FI3843723T3 (fi) 2026-02-12
JP7189327B2 (ja) 2022-12-13
JOP20190201B1 (ar) 2024-04-18
GEAP202215593A (en) 2022-07-11
EA202190622A1 (ru) 2021-06-10
SI3843723T1 (sl) 2026-04-30
AU2019328903B2 (en) 2023-01-05
RS67791B1 (sr) 2026-03-31

Similar Documents

Publication Publication Date Title
DK3843723T3 (da) Sammensætning til udryddelse af helicobacter pylori
DK3622079T3 (da) Sammensætninger til at gøre membranfusion lettere og anvendelser deraf
DK3283080T3 (da) Sammensætninger til modulation af c9orf72-ekspression
EP3922694A4 (en) WATER-REPELLENT COMPOSITION
EP3853332C0 (en) COMPOSITION
EP3663376A4 (en) WATER REPELLENT COMPOSITION
EP3882323A4 (en) COMPOSITION
DK3294831T3 (da) Sammensætning og fremgangsmåde til opfangning af sulfider og mercaptaner
DK3740475T3 (da) Fremgangsmåde til fremstilling af somatostatinmodulatorer
EP3862398A4 (en) Aqueous inkjet ink composition
ITUB20160413A1 (it) Metodo per determinare Helicobacter pylori
DK3840596T3 (da) Sammensætning
DK2956149T3 (da) Farmaceutiske sammensætninger til behandling af helicobacter pylori
EP3798251A4 (en) COMPOSITION OF HARDENABLE THIOL-ENE
SMT202300279T1 (it) Nuovi probiotici utili per eradicare l’infezione da helicobacter pylori
EP3897866C0 (en) ANTIMICROBIAL COMPOSITION
DK3468547T3 (da) Hidtil ukendte benzensulfonamidsammensætninger til behandling af maligne pleuraeffusioner
DK3856980T3 (da) Fremgangsmåde til stabilisering af jack-up-platformenhed
PT3765379T (pt) Composições
EP3790652A4 (en) IMPROVED WETTING COMPOSITION
DK3507282T3 (da) Fremgangsmåde til fremstilling af indolcarboxamidforbindelser
DK3527477T3 (da) Fartøj til bugsering af et andet fartøj
DK3891260T3 (da) Sammensætninger til udskylning af hydrogensulfid og methanthioler
EP3829532A4 (en) KERATIN COMPOSITIONS
DK3752129T3 (da) Torasemidsammensætning til multiple anvendelser